- Home
- LUCD vs SRZN Comparison
LUCD vs SRZN Comparison
Compare LUCD & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- SRZN
- Stock Information
- Founded
- LUCD 2018
- SRZN 2015
- Country
- LUCD United States
- SRZN United States
- Employees
- LUCD N/A
- SRZN N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- LUCD Health Care
- SRZN Health Care
- Exchange
- LUCD Nasdaq
- SRZN Nasdaq
- Market Cap
- LUCD 108.0M
- SRZN 120.0M
- IPO Year
- LUCD 2021
- SRZN N/A
- Fundamental
- Price
- LUCD $1.13
- SRZN $13.25
- Analyst Decision
- LUCD Strong Buy
- SRZN Strong Buy
- Analyst Count
- LUCD 5
- SRZN 2
- Target Price
- LUCD $3.70
- SRZN $38.50
- AVG Volume (30 Days)
- LUCD 637.8K
- SRZN 58.2K
- Earning Date
- LUCD 11-12-2025
- SRZN 11-07-2025
- Dividend Yield
- LUCD N/A
- SRZN N/A
- EPS Growth
- LUCD N/A
- SRZN N/A
- EPS
- LUCD N/A
- SRZN N/A
- Revenue
- LUCD $4,399,000.00
- SRZN $3,604,000.00
- Revenue This Year
- LUCD $13.30
- SRZN N/A
- Revenue Next Year
- LUCD $155.58
- SRZN N/A
- P/E Ratio
- LUCD N/A
- SRZN N/A
- Revenue Growth
- LUCD 5.01
- SRZN N/A
- 52 Week Low
- LUCD $0.75
- SRZN $5.90
- 52 Week High
- LUCD $1.80
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- LUCD 47.07
- SRZN 53.16
- Support Level
- LUCD $1.03
- SRZN $11.51
- Resistance Level
- LUCD $1.23
- SRZN $14.38
- Average True Range (ATR)
- LUCD 0.06
- SRZN 0.69
- MACD
- LUCD -0.02
- SRZN -0.16
- Stochastic Oscillator
- LUCD 34.62
- SRZN 61.54
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).